Mytus

Insulin Glargine (rDNA) USP

Composition : Mytus 100 IU vial : Each ml solution contains Insulin Glargine (rDNA) USP 100 IU.

Mytus 100 IU PenSet : Each ml solution contains Insulin Glargine (rDNA) USP 100 IU.

Indications : Mytus is indicated to improve glycemic control in adults and children with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.

Dosage and administration : Mytus exhibits a relatively constant glucose-lowering profile over 24 hours that permits once-daily dosing. Potency of insulin glargine is approximately the same as human insulin. Mytus is recommended for once daily subcutaneous administration & may be administered at any time during the day. However, once started should be administered at the same time every day. The dose of Mytus must be individualized based on clinical response. Blood glucose monitoring is essential in all patients with diabetes. In patients with type 1 diabetes, Mytus must be used in regimens with

short-acting insulin. Mytus is not recommended for intravenous administration. Intravenous administration of the usual subcutaneous dose could result in severe hypoglycemia. Injection sites should be rotated within the same region (abdomen, thigh, or deltoid) from one injection to the next. or, as directed by the registered physician.

Use in pregnancy and lactation : Pregnancy : Pregnancy category C. Insulin glargine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Lactation : lt is unknown whether insulin glargine is excreted in human milk. Because many drugs, including human insulin, are excreted in human milk, caution should be exercised when Insulin glargine is administered to a nursing woman. Lactating women may require adjustments in insulin dose & diet.

Storage : Store at 2ºC to 8ºC in a refrigerator. Do not freeze. Protect from light.

Packing : Mytus 100 IU vial : Each box contains 3 ml glass vial.

Mytus 100 IU PenSet : Each Box contains 3 ml glass cartridge.

Prescribing Description

Related Products

© Copyright Drug International Ltd. 2024 Designed and Developed by ATI Limited.